// App-Quantinova.ai

: Anti‐cardiolipin and Anti‐β2glycoprotein I IgA along with the Current Criteria Does Not Have an Added Value in Screening for Clinical Symptoms of the Antiphospholipid Syndrome

Researchers

Presenter

  • W. Chayoua

Principal Investigators

  • D.-M. Yin

  • H. Kelchtermans

  • G.W. Moore

  • J.-C. Gris

  • J. Musial

  • S. Zuily

  • B. de Laat

  • K.M.J. Devreese

Medical Centers

  • Cardiovascular Res Inst Maastricht, Maastricht Univ Medical Ctr, Maastricht, Netherlands

  • Synapse Research Institute, Maastricht, the Netherlands

  • Viapath Analytics, Guy's and St Thomas’ Hospitals, London, United Kingdom

  • Centre Hospitalier Universitaire de Limoges, Limoges, France

  • I.M. Sechenov First Moscow State Medical University, Moscow, Russia

  • Jagiellonian University Medical College, Cracow, Poland

  • Centre Hospitalier Regional Universitaire de Nancy, Université de Lorraine, Inserm, Nancy, France

  • Coagulation Laboratory, Ghent University Hospital, Ghent, Belgium

Locations

  • Netherlands

  • United Kingdom

  • France

  • Russia

  • Poland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Pulmonary/Respiratory Diseases

  • Blood/haematological Diseases

  • Cardiovascular (CVS)

Disease

  • Antiphospholipid syndrome

  • Venous thrombosis

Biomarkers

  • Cluster of differentiation 79A

  • Lactate

Drug/Treatment

  • Carbenoxolone sodium

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved